Released Oct 29, 2026, before the open
10-Q filed Oct 29, 2026, 29 days after period end · 0001104659-26-119864
In September 2026, the FDA granted nuzefatide ODD for the treatment of pancreatic cancer.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $34.06M | $11.73M | $2.68M | $5.35M |
| Net Income | -$10.48M | -$59.10M | -$50.80M | -$49.90M |
Bicycle Therapeutics PLC · CIK 1761612 · Engraved from SEC EDGAR
| EPS Diluted | -$0.15 | -$0.85 | -$0.74 | -$1.26 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicycle Therapeutics reported third quarter 2026 financial results on October 29, 2026, with cash and cash equivalents of $469.9 million as of September 30, 2026.¶2¶3
Collaboration revenue was $34.1 million for the three months ended September 30, 2026, compared to $11.7 million, primarily due to recognition of all remaining Bayer Consumer Care revenue upon termination of the collaboration.¶4
Research and development expenses were $33.4 million and general and administrative expenses were $14.1 million for the three months ended September 30, 2026, compared to $58.4 million and $18.9 million a year earlier.¶5¶6
Net loss was $10.5 million, or $(0.15) basic and diluted net loss per share, for the three months ended September 30, 2026, compared to net loss of $59.1 million, or $(0.85), for the prior-year period.¶7
The FDA granted nuzefatide pevedotin Orphan Drug Designation for pancreatic cancer in September 2026, and a Phase 2 trial in recurrent pancreatic ductal adenocarcinoma is actively enrolling patients.¶1¶8